DaVita Inc. (NYSE:DVA) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. trimmed its stake in DaVita Inc. (NYSE:DVA) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,092 shares of the company’s stock after selling 151 shares during the quarter. Vontobel Holding Ltd.’s holdings in DaVita were worth $313,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. FMR LLC grew its position in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA raised its stake in DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after buying an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares during the period. KBC Group NV raised its position in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in DaVita in the 3rd quarter valued at approximately $10,346,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 5.8 %

Shares of DVA opened at $145.99 on Friday. DaVita Inc. has a 12-month low of $119.42 and a 12-month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $11.68 billion, a price-to-earnings ratio of 13.59, a P/E/G ratio of 1.01 and a beta of 0.94. The stock’s 50-day moving average price is $161.24 and its 200 day moving average price is $157.81.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts predict that DaVita Inc. will post 10.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $162.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.